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Martínez Chanzá et al. (1) investigated the activity of 
cabozantinib (an inhibitor of multiple tyrosine kinase 
receptors) in a multicentre, retrospective, cohort study 
carried out by 22 centres that involved 122 patients with 
metastatic renal cell carcinoma (RCC) with confirmed 
non clear cell histology treated in any line of therapy 
between 2015 and 2018. In particular, the histologies 
were divided as follows: 59% papillary histology, 15% 
Xp 11.2 translocation, 13% unclassified histology, 9% 
chromophobe histology and 4% collecting duct histology. 
About 27% among these patients had an objective response 
to treatment [defined as the best radiological complete or 
partial response (PR) according to RECIST criteria]. At a 
median follow up of 11 months the median progression-free 
survival (PFS) was 7.0 months with a median overall survival 
(OS) of 12.0 months. The median time to treatment failure 
was 6.7 months (discontinuation of cabozantinib occurred 
mainly because of progressive disease in 85% of patients 
and, secondly, because of toxicity in 7% of patients). 
Cabozantinib was administered at the approved dose of 
60 mg one time a day to 83% of patients and the main side 
effects of any grade related to the treatment were similar to 
those seen with other TKIs (tyrosine kinase inhibitors) such 
as fatigue (52%), diarrhea (34%), rash and palmar-plantar 
erythrodysesthesia (31%), nausea (29%), hypertension 
(28%). In general, side effects were mostly mild to 
moderate and were generally manageable through the 
standard clinical practice. No deaths related to treatment 
were detected. Finally, next-generation sequencing 
(NGS) analysis were performed in 48% of patients which 
demonstrated that the most common somatic genetic 
alterations among all tumours were cyclin-dependent kinase 
Inhibitor 2A (CDKN2A) (22%) followed by mesenchymal 
epithelial transitions (MET) (20%). The authors concluded 
that cabozantinib showed encouraging activity and tolerable 
toxicity in all non-clear cell RCC, both in treatment-naïve 
patients and in heavily pretreated patients (24% of patients 
had had three or more previous systemic therapies) and the 
efficacy was maintained also in patients with poor-risk or 
intermediate-risk disease. These results connote that the 
antitumour efficacy of cabozantinib is not confined to clear 
cell histology only.
Cabozantinib is a TKI that targets several receptors 
such as vascular endothelial growth factor receptors 
1–3 (VEGFR 1–3), MET, AXL receptor tyrosine kinase 
(AXL) (2). Up to date, two large phase III trials (the 
METEOR trial (3) that compared cabozantinib with 
everolimus in patients progressed after previous VEGR-
targeted therapy and the CABOSUN trial (4) that 
compared cabozantinib versus sunitinib as first-line therapy) 
evaluated the activity and safety of cabozantinib in renal 
cancer patients with clear cell histology or at least a clear 
cell component. Based on the result of these trials, it has 
been speculated that cabozantinib may be considered a valid 
option also for non-clear cell histologies, that account for 
10–20% of all RCC.
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However, the treatment of non-clear cell RCC is very 
challenging because non clear cell RCC involve many 
histologies which are profoundly different according to 
prognosis, morphological and clinical characteristics, and 
genetic features (5,6). Papillary RCCs is divided into type 1, 
often sporadic and associated with epidermal growth factor 
receptor or alternatively MET mutations, and type 2, 
mostly associated with SETD2 mutations, CDKN2A 
mutations, TFE3 fusions or fumaratehydratase (FH) 
mutations, and characterised by aggressive phenotype 
and often positive family history (7,8). In chromophobe 
RCCs the most commonly oncogenic pathway implicated 
is mammalian target of rapamycin (mTOR) associated 
with tumour suppressor protein 53 (TP53) alterations 
(8-10). It has been reported that papillary and chromophobe 
histology account for 80% of non-clear cell RCC (5,6). 
Collecting duct carcinoma (CDC) is a rare and extremely 
aggressive RCC that develop, as its name suggests, from the 
renal collecting ducts and is distinguished by an immune 
profile with a high percentage of tumour infiltrating 
lymphocytes (11). 
The optimal treatment strategy for metastatic non 
clear cell RCC is still generally inferred from the evidence 
available for metastatic clear cell RCC. Unfortunately, 
due to the rarity of non-clear cell RCC tumours, only 
few prospective randomised trials have been carried out 
to date. In 2016, the results of two prospective phase II 
randomised trials (ASPEN and ESPN) have compared 
the activity of the VEGF-TKIs (sunitinib) to the mTORi 
(everolimus); both studies have shown improved PFS in the 
first line in patients treated with sunitinib. On the other 
hand, this benefit was not confirmed as regards the OS 
(12,13). Concerning the comparison between the survival 
outcomes for the metastatic non clear cell RCC group 
compared to the metastatic clear cell RCC group, a large 
retrospective analysis of the International Metastatic RCC 
Database Consortium (IMDC) (14) showed that the entire 
non clear cell RCC group had a worse OS than the clear 
cell RCC group; the median OS was 12.8 months versus 
22.3 months in clear cell RCC (P<0.0001). By contrast, 
the chromophobe non clear cell RCC subtype had a survival 
outcome which was comparable to clear cell RCC, except 
for the chromophobe tumours with sarcomatoid features 
which are associated with poor prognosis (15). 
In addition, a recent retrospective study, although 
involving only Asian patients (16), confirmed that the 
survival outcomes for the metastatic non clear cell RCC 
cohort were significantly inferior to the outcomes for the 
metastatic clear cell RCC cohort regarding to first-line 
PFS, total PFS, and cancer specific survival (CSS), except 
for the chromophobe and Xp 11.2 translocation groups 
that showed better survival outcomes compared to clear 
cell RCC. Contrariwise, first line PFS, total PFS and CSS 
for the other histologies evaluated in this study (like the 
collecting duct, papillary, and unclassified groups) were 
meaningfully poorer compared to those of the group clear 
cell RCC. Another retrospective study carried out by 
Koshkin et al., whose results were presented at the American 
Society for Clinical Oncology (ASCO) genitourinary (GU) 
conference in San Francisco in 2017, demonstrated the 
activity and safety of nivolumab in non-clear cell RCC 
subtypes (17). Twenty-three patients with metastatic non 
clear cell RCC were treated with nivolumab between 
12/2015 and 01/2017. The most represented histologies 
were unclassified (48%) and papillary (44%) and most 
patients had been pretreated with systemic therapy (mainly 
sunitinib, pazopanib or axitinib). After a median follow up 
of 6.5 months, median PFS was 4.2 months and median OS 
was not reached. Twenty-nine percent patients had PR as 
the best radiological response and 19% had stable disease 
(SD). Median time to best response was 5.1 months (17). 
With regard to cabozantinib, a retrospective study 
demonstrated a promising efficacy in patients with 
metastatic non clear cell RCC with a 14.3% of patients who 
had confirmed PR, and 64.2% who had SD. The median 
PFS was 8.6 months and the median OS was 25.4 months at 
a median follow-up of 20.6 months (18). 
Despite its clear importance and value, the study by 
Martínez Chanzá et al. presents several limitations that 
we have to address. First of all, the retrospective analysis 
could cause possible selection bias. In addition, we have 
to mention the population heterogeneity regarding 
histology and clinical history, even if the cohort analyzed 
is correctly evocative of the actual population treated in 
clinical practice. It is quite important to mention the lack 
of central pathological and radiological review and the use 
of the time to treatment failure rather than the progression 
free survival as one of the main endpoint (by reason of the 
discontinuation of the treatment that was not necessarily 
due to tumour progression, but rather to the physician’s 
judgment based on patient tolerability and clinical 
benefit). To conclude, the ability to evaluate the efficacy 
of cabozantinib also in relation to the tumour genomic 
alterations, was possible only in a small number of patients 
(although this is the biggest series reported so far).
In  conclus ion,  non-c lear  ce l l  RCC inc ludes  a 
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heterogeneous group of tumours different from each other 
in terms of clinical features, genetic characteristics and 
prognostic variables, which are scarcely investigated due to 
their infrequency. It is crucial to define the efficacy of the 
available treatments and the best treatment sequence for 
this group of patients, because few studies have been carried 
out on the matter and it is not certain whether the data 
obtained for patients with clear cell histology can also be 
completely applied to patients with non-clear cells histology. 
For these reasons, the importance of the study carried out 
by Martínez Chanzá et al., and of the other studies that have 
been done with similar intent, is noteworthy. 
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